Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln

Intercept Pharmaceuticals

26/09/2023 13:08

Sept 26 (Reuters) - Italy's Alfasigma S.p.A said on
Tuesday it had agreed to buy U.S. drugmaker Intercept
Pharmaceuticals  ICPT.O  for $794 million to expand its presence
in the United States.
    Alfasigma will pay $19 per Intercept share, which represents
a premium of 82% to its last closing price.

 (Reporting by Manas Mishra in Bengaluru; Editing by Shilpi
Majumdar)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))